There is a long history of hyperthermia in oncology, but its wide range acceptance and application is missing even today. A new approach of oncological hyperthermia, oncothermia, looks promising modality of the complementary treatment of advanced malignant cases. Our present article is targeting this method, trying to answer on the question of its feasibility to treat various advanced cases in monotherapy process, as well as its applicability for a long, large number of treatment sessions protocols.
These popular treatment applications of heating are types of "kitchen medicine": the old recipes are "sure", the patient takes it, and cured when it is done according to the auricular traditional regulations. This "for sure" is the disadvantage of the popular wisdom. It interprets this heating method as a simple causal process, "do it, get it". However, the hyperthermia is not as simple as the traditions interpret it. Internal source of heat is the fever as a reaction to infections [1] or pyrogens [2] or malignant hyperthermia [3] as well. The natural fever is induced by the living system [4] . The situation is quite different, when the heating is forced from outside of the body and it is intended to be applied as therapy. The forced heating works against the homeostasis and the body tries to keep the temperature normal, irrespective that the heating is local, regional or systemic. The interpretation of hyperthermia as therapy has various stumbling-blocks, because the effect caused by the absorbed heat is too complex: the applied, absorbed energy is usually depleted non-homogeneously and the intricacy of the living processes modifies the intended motive of application. Further complication is/in the heating process itself: the efficacy certainly differs by heat-sources and by the properties of the target volume and its physiological effects as well. A frustration in understanding of the differences between the natural and constrained heat-therapies and their consequent reactions characterizes the complete history of hyperthermia in medicine, and explains in majority why hyperthermia has no well deserved place in the professional medical armory to treat various diseases. Hyperthermia as a treatment modality is battling for the step from the bio-medical experiment status to a clinically proven one [5] , [6] .
The central problem of the forced heating in a local/regional volume is the physiological feedback reaction acting to compensate the compulsory temperature elevation. The main physiological feedback mechanism is the active blood-flow in the heat-targeted volume, [7] , [8] , [9] . The intensified blood-flow is excellent heat-exchanger, cooling down the heated volume and effectively increasing the temperature in the sorrounding of the target. The high blood-flow delivers extra nutrients (malinly glucose) supplying the tumor, as well as increases the risk of dissemination of malignant cells by the blood-stream. Both effects are contrary to our direct aim to destroy the cancer. The situation is a competition now between the cellular distrotion by direct heat and the supply of the growth of the tumor together with its increasing dissemination ability. This is the origine of the contradictiong results and the missing satisfactory control on the oncological heat-treatments. Technically a huge variety of heating could be applied by heat therapies [10] . Its energy-production, its selectivity, locality, kind of energy-delivery, locality invasivity control, applied frequency of the electromagnetic waves, as well as their medical applications and combination with other methods make Oncothermia Journal, June 2013 the heat-therapies different. Oncothermia is a special heating, targeting the membrane of the malignant cells [11] . This nano-range heating makes possible to destroy the malignant cells by extreme temperature gradient on their membranes individually [12] 
Case-reports
Rectosigmoid cancer with liver metastasis 
Before oncothermia After 12 times of oncothermia After 31 times of OncoTx
Tumor mass in liver was regressed and liver parenchyma increased gradually with concurrent small dose of radiation and oncothermia. No adverse effect originated from oncothermia was observed. This result gives the large possibilities of combined treatment of oncothermia with low dose of radiation for far advanced cancer for palliative treatment.
Hepatocellular carcinoma
A 61-year- 
Pancreatic cancer
A 59-year-old Asian woman had been diagnosed as Pancreatic cancer in Aug/2010. Chemotherapy was given many times as much as possible at other hospitals. She visited Kosin University first in Aug/2011 just only to relieve massive pain for serious carcinoma peritonei with conglomerated mass attached at anterior abdominal wall. Radiation therapy was given 30 Gy in 10 fractions(once/day, for 2 weeks) With IGRT technique to anterior abdominal wall mass in August/2011. Ascites was not at that time.
Abdominal pain was relieved much just after palliative Radiation Therapy but progressed gradually from Oct/2011. Ascites and intestinal obstruction were developed. Intestinal bypass surgery was recommended by surgeon but was not performed. It was difficult to recover from the high risk of the operation since the patient had far advanced cancer and poor general condition. Oncothermia was started firstly in our hospital as soon as installed in November 2011. She could eat some food and ascites was controlled by medicine since 5 times of oncothermia were given. Cancer mass was regressed a little bit. Amount of analgesics intaken was reduced. She maintained well with oncothermia to later June 2012. But her cancer became worse gradually. Eventually cancer metastasis to both pleural cavity was developed with both pleural effusion. Patient's general condition became worse gradually for pleural metastasis. That was drained often to reduce dyspnea. It was difficult to keep hyperthermia for 1 hour due to the poor general condition and inevitably carcinoma peritonei became worse from August 2012. She died due to pneumonitis with massive pleural effusion on the early September 2012. Although she had a massive abdominal pain because of far advanced carcinoma peritonei, she lived for 10 months by controlling the massive abdominal pain with Oncothermia. She was the first patient to be applied Oncothermia. From her case, there are many possible cases applied to other patients of advanced cancer with oncothermia without any negative side effects. Total 82 times of oncothermia to her were given by 2~3 times/week to her for 10 months. It can be possible to apply many times of oncothermia for advanced cancer without any complications.
Synovial sarcoma
This 48 Metastatic sarcoma to lung was markedly regressded with oncothermia. Sarcoma has been already known to be sensitive to hyperthermia. And also Sarcoma is sensitive to oncothermia as well.
Pancreatic cancer
A Metastattic bladder cancer was regressed prominently after 12 times of oncothermia. Pancreatic tumor mass was also reduced in the size prominently after oncothermia. If the primary tumor was sensitive to oncothermia metastatic cancer is also sensitive to the oncothermia. But she got sudden death on Sept/3/2012 due to brain edema for aggravation of metastatic brain tumor. Tumor mass at left hilum was regressed markedly in chest CT scan after 24 times of oncothermia with 30 Gy of Radiation therapy. Adenoid cystic carcinoma is generally resistant to Radiation therapy. But concurrent Radiotherapy and Oncothermia made these metastatic lung cancer reduced in size.
Adenoid cystic carcinoma

Lung cancer
A 55-year-old Asian man was diagnosed as lung cancer(adenocarcinoma) in March 2010 and received chemotherapy and target therapy. He received Radiotherapy at regrowing lesion with invasion to spine at the operated site and Rib delivering 30 Gy in 10 fractions for 2 weeks in April 2011. tumor mass regrew and multiple metastatic lesions was appeared in both lung. Oncothermia was given 24 times(2~3 times/week) from April/10/2012 to July/12/2012.
Before HTx After HTx 12 times
Tumor mass was regressed at the right lung and spine. However tumors were progressed in the left lung because oncothermia was not given at the left lung. Back pain to the right chest was subsided after oncothermia. Many cases were shown the reduction of the metastatic bone pain with oncothermia. It is possible to apply oncothermia to reduce metastatic bone pain with a variety of cancer. Tumor mass of bladder was regressed after 24 times of oncothermia. As can be seen the result of CT scan taken after 2 months stopped oncothermia, the futher regression of the tumor mass was observed. That is, even though the oncothemia treatments was stopped, the effectiveness in the reduction of tumor mass was kept for 2 months.
Bladder cancer
67-year-old
Lung cancer
This 47year old female was diagnosed as Lung Cancer(adenocarnoma) in April/2010 Chmotherapy and target therapy were given up to Oct/2011. However, no longer those treatments were affected to the patient from the early Dec. 2011. 12 times of Oncothermia (2~3 times/week) were given from Dec/22/2011 to Feb/2/2012.
Before OncoTx After 12 times of OncoTs 4 Months from OncoTx
Tumor mass was regressed markdely just after oncothermia. However tumor mass was progressed rapidly in 4 months of stopping oncothermia. Original tumor mass in the area of oncothermia was regressed. But new lesion at the outside of oncothermia region was progressed gradually. She died in Aug/2012 due to liver, brain, multiple bone metastasis and massive aggravation of the lung cancer.
Pancreatic cancer
A 68-year-old Asian man was one of patients who received many times of oncothermia. Pancreatic cancer was diagnosed in August 2011. He refused chemotheray from diagnosis. Operation was impossible to be performed at the time of the diagnosis. Oncothermia9@~3 TIMES/WEEK) was given 65 times from February/16/2012 to October/11/2012. Tumor mass recurred from post ovarian cancer in pelvis was regressed markedly after oncothermia 12 times and ascites was improved and controlled by medicine.
Stomach cancer
This 50 Before Oncothermia After 12 times of oncothermia Any negative side effects were not appeared even though the high temperature had been expected at the metal stent site. Metal stent in the canal or duct is not absolute contra-indication for oncothermia. Duodenal stent disappeared after oncothermia but patient could eat food well with good food passage through duodenum. Tumor mass maybe was also regressed by oncothermia.
54-year-old woman has been diagnosed as Stomach Cancer with metastasis to right ureter in Jan/2012. The patient had inoperable state and refused chemotherpy by herself. 36 times(2~3 times/week) of oncothermia were given from April/17/2012 to Sep/6/2012. lung. CT scan was checked, too. Tumor mass regressed prominently at left lung. However those at right lung did not regressed in size, furthermore some progressed. And the pain posterior to left upper chest because of metastatic cancer with invasion to chest wall was also relieved after oncothermia. This case is not oncothermia monotherapy but It must be sure in this one film that the combined chemotherapy with oncothermia is more effective certainly.
Renal cancer
A 61-year-old man was diagnosed as renal cell carcinoma in Jan/2011. He refused to get any special treatment for cancer like chemotherapy, hormonal therapy, target therapy, operation and radiotherapy. He received only oncothermia 24 times(2 times/week) to tumor mass at left upper abdomen from Dec/2/2011 to Feb/23/2012 for 3 months.
Before oncothermia 24 times of oncothermia
Lung
A 86-year-old man checked Computerized tomography (CT) scan due to symptoms of the upper respiratory infection. CT scan showed a mass at the right lower lung and mediastinal area but we could not performed biopsy because of the high risk of procedure. The patient had inoperable state and refused chemotherapy by himself. He received Radiotherapy 30Gy in 10 fractions(once/day) for 2 weeks and concurrent oncothermia 22 times(2~3 times/week) from January/27/2012 to March/6/2012.
Before Oncothermia After 12 times oncothermia
Tumor was regressed after 22 times of oncothermia. Combined treatment of the small amount of radiation and oncothermia revealed the prominent regression of lung mass even through histologic type were not confirmed. Tumor makers of CEA 5.99 and NSE 38.97 were abnormal level in serum.
Conclusion
These cases together with the huge amount of other treatments answers on our questions, however of course further investigations and studies are mandatory. We had not observed oncothermia related adverse effects by dose-escalation. In negligible case skin erythema appeared, handled with appropriate cream. It did not terminated any further treatments.
Oncothermia could be applied in very severe cases, where other treatments are dubious or inapplicable. In this situation oncothermia could be applied as monotherapy with success. On the other hand the complementary applications of oncothermia had no any limitations for the oncothermia side of the therapy. We observed some cases which are not eligible for oncothermia, due to the mismatch of the electrodes, the bolus is not able to cover the surface smoothly. We had no contraindicated cases in our patient spectra. The efficacy of the treatment was depending on the number of applied sessions. The long-time applications were positive for the patients in both the curative and quality of life meanings in advanced diseases.
